The efficacy of Andrographis paniculata (Burm.f.) Wall. ex Nees crude extract in 1

hospitalised mild COVID-19 patients: a retrospective cohort study 2

- 3 Authors
- Jeeranan Tanwettiyanont^a, Napacha Piriyachananusorn^b, Lilit Sangsoi^b, Benjawan Boonsong^b, Chamlong 4
- Sunpapoa^c. Patcharawan Tanamatavarat^{d-e}. Sukrit Kanchanasurakit^{a-b,f-h*}. and Nat Na-Ek^{i-j,*} 5

6 Affiliations

- 7 ^a Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences,
- 8 University of Phayao, Phayao, 56000 Thailand
- 9 ^b Division of Pharmaceutical care, Department of Pharmacy, Phrae Hospital, Phrae, 54000 Thailand
- ^c Division of Internal Medicine, Department of Nurse, Phrae Hospital, Phrae, 54000 Thailand 10
- 11 ^d Division of Pharmacy and Technology, Department of Pharmaceutical Care, School of Pharmaceutical
- Sciences, University of Phayao, Phayao, 56000 Thailand 12
- 13 ^e Unit of Excellence Technologies for Natural Products and Herbs, School of Pharmaceutical Sciences,
- 14 University of Phayao, Phayao, 56000 Thailand
- 15 ^f Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical
- 16 Sciences, University of Phayao, Phayao, 56000 Thailand
- 17 ⁹ Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical
- 18 Sciences, University of Phayao, Phayao, 56000 Thailand

19 ^h Unit of Excellence on Herbal Medicine. School of Pharmaceutical Sciences. University of Phavao. Phavao.

- 56000 Thailand 20
- ⁱ Pharmacoepidemiology, Social and Administrative Pharmacy (P-SAP) research unit, School of 21
- Pharmaceutical Sciences, University of Phayao, Phayao, 56000 Thailand 22
- 23 ^j Division of Social and Administration Pharmacy, Department of Pharmaceutical Care, School of
- Pharmaceutical Sciences, University of Phayao, Phayao, 56000 Thailand 24
- 25 **Corresponding author***
- 26 Nat Na-Ek, PharmD MSc PhD, E-mail: nat.na@up.ac.th
- 27 And
- 28 Sukrit Kanchanasurakit, PharmD, E-mail: sukrit.ka@up.ac.th
- 29

1 Abstract

2 Background: Andrographis paniculata (AP) crude extract has been widely used in Thailand to treat mild 3 COVID-19 infection since early 2020; however, supporting evidence was lacking.

4 Purpose: To evaluate the efficacy of AP compared with standard treatment among hospitalised mild COVID-5 19 patients.

6 Study design: Single-centre retrospective cohort study

7 Methods: We collected data between March 2020 and August 2021 from COVID-19 patients admitted to one 8 hospital in Thailand. Patients whose infection was confirmed by Real-Time Polymerase Chain Reaction (RT-

9 PCR) and had normal chest radiography were included, whereas those receiving favipiravir or had unclear

10 chest X-rays at admission were excluded. Participants were categorised as either AP or standard of care and

11 followed for pneumonia confirmed by chest radiography. Multiple logistic regression was used to analyse the

12 main results controlling for age, sex, history of having diabetes, hypertension, receiving statins, and

13 antihypertensive drugs.

14 Results: 605 out of 1,054 patients were included in the analysis. Of these, 59 patients (9.8%) developed 15 pneumonia during the median follow-up of 7 days. The incidence rates of pneumonia were 13.93 (95%Cl 10.09,

19.23) and 12.47 (95%Cl 8.21, 18.94) per 1,000 person-days in AP and standard of care group, respectively. 16

Compared to the standard of care group, the odds ratios of having pneumonia in the AP group were 1.24 17

18 (95%CI 0.71, 2.16; unadjusted model) and 1.42 (95%CI 0.79, 2.55; fully adjusted model). All sensitivity analyses

19 produced consistent findings with the main results.

20 Conclusion: We do not have sufficient evidence to show the efficacy of AP in mild COVID-19 infection.

21 Interestingly, we observed the potentially harmful signal of using AP. While waiting for insights from ongoing 22 trials, AP's use in this condition should be done with caution.

23 Keywords: COVID-19, hospitalisation, Andrographis paniculata, andrographolide, pneumonia

24 Key points

- 25 What is already known about this subject?
- 26 Andrographis paniculata (AP) has been used to treat COVID-19 in Thailand since early 2020.
- 27 Clinical evidence supporting the use of AP in COVID-19 infections is still lacking.
- 28 What does this study add?
- 29 We had insufficient evidence to show the efficacy of using AP in mild COVID-19 cases.
- 30 AP might be potentially associated with an increased risk of pneumonia.
- 31 How might this impact clinical practice?
- 32 While waiting for the ongoing trials, using AP in COVID-19 should be suspended.

33

1 Introduction

- 2 Andrographis paniculata (Burm.f.) Wall. ex Nees (AP), also known as 'Fa Thalai Chon' or 'Fa Thalai', has been 3 widely used in Thailand for treating upper respiratory tract infections and non-infectious diarrhoea after being
- 4 in the National List of Herbal Medicines of Thailand in 1999 (Karbwang and Na-Bangchang, 2021). The main
- 5 phytochemical constituent of the aerial parts of AP is a diterpenoid lactone compound called 'andrographolide',
- 6 which has shown antiviral and immunomodulatory properties from preclinical and clinical studies (Dai et al.,
- 7 2019). Recently, in silico study has shown the potential effect of andrographolide on SAR-CoV-2 as the
- 8 compound can bind and inhibit the viral protease enzyme and viral spike glycoprotein (Enmozhi et al., 2021;
- 9 Rajagopal et al., 2020). Moreover, in vivo and in vitro studies consistently supported the effect of AP extract
- 10 on COVID-19 infections (Phumiamorn et al., 2020; Sa-ngiamsuntorn et al., 2021).
- 11 In addition to preclinical studies, two small clinical trials of using a high dose of AP crude extract to treat mild 12 COVID-19 infections has shown its efficacy in terms of reducing COVID-19 symptoms (Rattanaraksa et al., 13 2021) and C-reactive protein (CRP) levels (Wanaratna et al., 2021). However, its efficacy on an important 14 clinical outcome, such as pneumonia, is unclear. This is because the results from the trial of 57 patients had
- 15 shown no significant decrease in the incidence of pneumonia in the AP group, compared to placebo, after five
- 16 days of treatment (p-value = 0.11) (Wanaratna et al., 2021). Currently, five ongoing trials are investigating the
- 17 efficacy of AP in terms of pneumonia for treating mild COVID-19 cases.
- 18 Although AP's efficacy on the major clinical endpoint is still ambiguous, its widespread use has been 19 encouraged. This is due to the situation in which Thailand experienced a shortage of favipiravir and COVID-19 20 vaccines at the start of a new pandemic wave in early 2020. Therefore, the data on the efficacy and safety of 21 AP from a pharmacovigilance study is necessary to support the decision of clinicians and policymakers whether
- 22 AP's use in COVID-19 should be further supported.
- 23 In this study, we primarily aim to use real-world data to investigate the efficacy of AP crude extract for the 24 treatment of hospitalised mild COVID-19 patients. We also examined the course of COVID-19 and the incidence 25 of pneumonia due to COVID-19 in a country-specific context. Our ultimate goal is to make the best use of 26 available data to inform the public and improve patient care.

27 Methods

- 28 The report of this study followed the Strengthening the Reporting of Observational Studies in Epidemiology
- (STROBE) guidance for reporting cohort study (Vandenbroucke et al., 2007) (Table S1). 29
- 30 Design, setting, and study population
- 31 This is a single-centre retrospective cohort study in which the data were collected from medical records of patients diagnosed with COVID-19 infection. We used the 10th revision of the International Classification of 32 Diseases (ICD-10) code U07.1 to identify potential participants from 1st March 2020 to 31st August 2021. The 33 34 ethical committee for clinical research of Phrae hospital approved this study (no. 70/2564).
- The setting of our study is Phrae hospital, a 500-bed secondary hospital located in northern Thailand. Eligible 35 36 participants were at least 18 years old and diagnosed with COVID-19 infection by Real-Time Polymerase Chain 37 Reaction (RT-PCR) test. According to the definition of mild COVID-19 used in previous work (Zhang et al., 38 2021), we included only patients who had normal chest radiography by the time of hospital admission. In contrast, individuals who did not have chest radiography results received antiviral drugs (i.e., favipiravir) or 39 40 received systemic corticosteroids on the first day of admission were excluded. In addition, we also excluded

1 those who recently received AP prior to hospital admission, had a history of allergy to AP, had elevated liver 2 enzyme, or were pregnant or breastfeeding from the analysis. Since the preliminary data suggested that AP's 3 efficacy was shown if it was given to patients as soon as they were diagnosed, we additionally excluded 4 patients who received AP after five days of admission from our analysis. (Thai Clinical Trials Registry, 2009)

5 Exposure

6 Included participants who received AP crude extract within five days of admission in addition to a supportive 7 treatment were categorised as an exposed group. AP crude extract was given as a capsule of 500 mg of crude 8 extract containing andrographolide content of approximately 4%w/w (~20 mg/capsule). According to a previous 9 trial, (Wanaratna et al., 2021) the AP product was given three capsules thrice daily after a meal to reach a total 10 dose of andrographolide 180 mg/day for five consecutive days. Song hospital, Phrae, Thailand, produced the 11 AP product used in this setting. The quality of AP product was tested and certified by the Medicinal Plant 12 Research Institute and the regional Medical Sciences Centre, Chiang Rai, Thailand (details can be found in 13 supplementary appendices). Supportive treatment, including antipyretics, mucolytics, expectorants, 14 antihistamines, oral rehydration salts, and anxiolytics, was given to patients who did not receive AP (unexposed 15 group).

16 Outcomes

17 The primary outcome was developing pneumonia based on chest radiography during hospital admission. The 18 diagnosis of pneumonia was based solely on chest X-rays (CXR) of category four or above according to the 19 Modified Rama-Co-RADS for the first CXR in confirmed COVID-19 patients (Supplementary appendices). The 20 categorisation was made mainly by infectious disease physicians or radiologists. Patients with ambiguous CXR 21 results were excluded from the analysis. For patients who did not have CXR results during follow-up and did 22 not die or refer to the intensive care unit, we assumed that they did not develop pneumonia and used discharged

23 date as the end of the follow-up.

24 In addition, we analysed the association between receiving AP and a secondary outcome, which was a 25 composite of receiving favipiravir, systemic corticosteroids, or ventilator support; having oxygen saturation drop 26 along with worsening signs and symptoms; or presenting regressive CXR findings (i.e., category three or above) 27 after admission. The CXR results, all clinical data, and relevant medications were collected from electronic 28 medical records.

29 Covariates

30 We collected all covariates for the admission date from medical records. These covariates included age, sex, 31 weight, height, comorbidity, current medications, and laboratory parameters. According to our proposed directed 32 acyclic graphs (DAGs, Figure S1), age, body mass index, hypertension, type 2 diabetes (T2DM), ACEIs/ARBs, 33 statins, and COVID-19 severity were associated with both receiving AP (from discussion with a health care 34 team) and developing pneumonia (Table S5) (Centers for Disease Control and Prevention, 2021a, 2021b) and 35 did not lie in a causal pathway between these two variables and were thus considered confounders. Admittedly, 36 during the data collection period, there were only two patients who had received a COVID-19 vaccine before 37 diagnosis and hospital admission. Consequently, we did not include vaccination profiles in our analysis.

38 Statistical methods

In this study, we included all eligible COVID-19 patients in the analysis. Therefore, sample size calculation was 39 40 unnecessary, and we planned to calculate statistical power afterwards. Descriptive and inferential statistics

1 were used to compare participants' characteristics at hospital admission according to their exposed groups. In

2 addition to the calculated incidence rate of pneumonia (per 1,000 person-days) according to exposed groups, 3 a Kaplan-Meier plot for the probability of a pneumonia-free event between groups was also created and

4 statistically compared using a log-rank test.

5 The main analysis was performed using a multivariable logistic regression based on a complete-case approach. 6 The justification for using a logistic model is that each participant had a relatively similar follow-up time: a 7 median of 7 days (interguartile range 6 to 9 days). To investigate the association between receiving AP and 8 incident pneumonia, we did serial adjustment as follows: 1) unadjusted model, 2) age-adjusted model, and 3) full adjustment (i.e., adjusting for age, hypertension, T2DM, ACEIs/ARBs, and statins). Regarding BMI, we 9 10 further performed multiple imputations by chain equation (MICE) to impute missing values. In addition to all 11 variables in the main analysis, the following auxiliary variables were added to the imputation model: follow-up time, age², Nelson-Aalen cumulative hazard function, the use of proton pump inhibitors at baseline, weight, 12 height, and alkaline phosphatase (logarithmic scale). BMI was then included in a model as part of a sensitivity 13 14 analysis since we assumed that the missing BMI values were unlikely to be under a missing at random (MAR) 15 mechanism (i.e., there are other variables significantly affecting BMI that were not recorded and collected, such 16 as daily caloric intake, physical activity, and smoking status) and using MICE might bias the results. We 17 performed 100 imputations, and results were combined using Rubin's rule.

18 Moreover, for the sensitivity analysis, we analysed the data using Cox's proportional hazards model, in which 19 a fully adjusted model was stratified by diabetes. The Schoenfeld residuals test and log-minus-log plots were 20 checked accordingly to ensure the satisfaction of the proportional hazards assumption. The severity of COVID-21 19 was conditioned by restricting the analysis to a mild case only. Furthermore, we performed subgroup 22 analyses according to sex, age group (i.e., <60, ≥60), hypertension, T2DM, ACEIs/ARBs, and statins to 23 examine effect modifiers. Lastly, to minimise a cohort effect due to differences in admission period, since some 24 patients in an unexposed group were admitted a few months before an exposed group (Figure S3) and 25 guidelines for COVID-19 treatment and coverage of immunisation can improve drastically over a short period, we, therefore, excluded individuals admitted before the 1st of July, 2021, then re-analysed the main group of 26 27 patients.

28 All analyses were performed using STATA version 16.1MP (StataCorp LLC, College Station, Texas) and R 29 version 3.3 with a two-sided alpha error of 5%. As we did not adjust for multiplicity, findings of the secondary

30 outcome, sensitivity analyses, and subgroup analyses should be used for exploratory purposes only.

31 Results

32 Among 1.054 COVID-19 patients admitted to the hospital between March 2020 and August 2021, 605 were 33 included in the final analysis (Figure 1). Of these, 351 individuals (58%) received AP within five days of 34 admission. Regarding the characteristics of included participants at hospital admission (Table 1), the majority 35 of the participants were male (50.4%), with a mean age of 35.41 years old and a mean BMI of 24.2 kg/m². 36 Only a small proportion of individuals had hypertension (7.3%), T2DM (2.2%), and cardiovascular disease 37 (0.8%). In addition, 3.8% and 2.6% of the patients received ACEIs/ARBs and statins, respectively. Comparing between groups, most of the characteristics were relatively similar, except for alkaline phosphatase (ALP) 38 39 levels, as the levels in the AP group were slightly higher than in the standard of care group. However, all 40 laboratory parameters were within the normal range (Table 1).

1 During a median follow-up time of 7 days (IQR 6, 9 days) and a median hospital stay of 8 days (IQR 6, 10 2 days), 59 out of 605 participants (9.8%) developed pneumonia - an overall incidence rate of 13.35 (95% CI 3 10.34, 17.23) per 1,000 person-days. Comparing between groups, 37 out of 351 individuals (10.5%) in the AP group developed pneumonia, whereas 22 out of 254 patients (8.7%) in the standard of care group developed 4 5 pneumonia. This corresponded to a slightly higher (but not statistically significant) incidence rate of pneumonia 6 in the AP group (13.93 [95% CI 10.09, 19.23] per 1,000 person-days) than in the standard of care group (12.47 [95% CI 8.21, 18.94] per 1,000 person-days (log-rank p-value = 0.69, Table S3 and Figure S2). According to 7 8 Table S3-S4, it is worth noting that, regardless of exposure group, 1) the incidence rate of pneumonia before 9 seven days of follow-up was higher than that afterwards, and 2) the incidence rate of pneumonia among 10 patients aged over 60 years was drastically higher than that among younger individuals.

11 According to Table 2, compared to a standard of care, receiving AP was associated with increased but not 12 statistically significant odds of having pneumonia: odds ratio (OR) of 1.24 (95% CI 0.71, 2.16), 1.42 (95% CI 13 0.80, 2.54), and 1.42 (95% CI 0.79, 2.55) in an unadjusted-, age-adjusted-, and fully adjusted-model, 14 respectively. Furthermore, considering follow-up time and censoring yielded slightly attenuated but consistent results: hazard ratio of 1.11 (95% CI 0.66, 1.89), 1.26 (95% CI 0.74, 2.15), and 1.26 (95% CI 0.74, 2.17) in 15 16 unadjusted-, age-adjusted-, and fully adjusted-model, respectively. Additionally, receiving AP was also 17 associated with a slight but not significant increase in the odds of worsening symptoms. Further adjusting for BMI did not change the direction of the association (Table S6). 18

Interestingly, excluding participants admitted before the 1st of July, 2021 (most were from the standard of care 19 20 group) further strengthened the association of receiving AP with the increased odds of having outcomes. The 21 OR of having pneumonia in an unadjusted-, age-adjusted-, fully adjusted-model, and a model additionally 22 adjusting for BMI was 1.83 (95% CI 0.93, 3.61), 1.94 (95% CI 0.97, 3.92), 1.88 (95% CI 0.92, 3.81), and 1.72 23 (95% CI 0.78, 3.79), respectively (Table S6).

24 Results from subgroup analyses are shown in Figure 2. It can be observed that sex was not an effect modifier 25 of the association between receiving AP and pneumonia. However, the association seems stronger among the 26 elderly (i.e., >60 years). Although AP might be related to the increased risk of pneumonia in overall populations 27 and all p-values for interaction >0.05, we found the opposite direction of the associations among individuals

28 with hypertension, receiving ACEIs/ARBs, and receiving statins.

Discussion 29

30 Summary of the main findings

31 In this retrospective cohort study of 605 hospitalised COVID-19 patients who had normal chest radiography at 32 the time of admission, 9.8% of them developed pneumonia after a median follow-up time of 7 days. However, 33 we did not have sufficient evidence to show the efficacy of AP crude extract in decreasing the risk of pneumonia 34 or worsening clinical symptoms. Interestingly, individuals, mainly the elderly, receiving AP were associated with 35 an increased, but not statistically significant, risk of pneumonia and worsening clinical symptoms. Moreover, all 36 sensitivity analyses provided consistent findings, ensuring the robustness of the main results.

37 Compared with previous studies

38 So far, the clinical evidence of using AP to treat COVID-19 is still lacking. After performing a systematic search 39 on three databases (i.e., PubMed, Google Scholar, and Thai Clinical Trial Registry), we found only two complete 40 trials (Rattanaraksa et al., 2021; Wanaratna et al., 2021) and five ongoing trials relevant to this subject, with 41 the largest trial of 736 patients expected to end in October 2022 (Table S2). One trial investigated the efficacy

1 of AP in improving clinical symptoms and duration of disease in 62 mild COVID-19 patients (Rattanaraksa et 2 al., 2021). It showed that all COVID-19 symptoms in the AP group had disappeared by day 7 (i.e., two days 3 after completing an AP course). Compared with our observation, the median length of hospital stays before 4 being discharged alive in an AP group and a standard of care group was eight days (IQR 6, 10 days) and 5 seven days (IQR 6, 9 days), respectively. Therefore, the course of the disease in ours was comparable to the 6 previous one. Another trial reported the incidence of pneumonia in the AP group (0%) and the placebo group 7 (10.7%) after five days of treatment (Wanaratna et al., 2021). The figure was similar to the incidence of 8 pneumonia in our study's standard of care group (8.7%), confirming the validity of our collected data. 9 Furthermore, we found that increased age, having hypertension and diabetes, and receiving ACEIs/ARBs and 10 statins were associated with an increased risk of pneumonia (Table S5). This is consistent with previous reports (Centers for Disease Control and Prevention, 2021b, 2021a) and can further ensure the validity of the data 11 12 used in our analyses.

13 Strengths and limitations

14 To the best of our knowledge, this is the first cohort study of AP's use in treating mild COVID-19. Admittedly, 15 Thailand was confronted with the favipiravir and vaccine shortages at the beginning of the second wave of the 16 pandemic crisis, leading to the unproven AP's use for this condition. Consequently, a pharmacovigilance study is required since the real-world data from using AP has been already available so that its efficacy and safety 17 18 can be clinically ensured.

19 However, there are some limitations worth noticing. First, we cannot avoid residual confounders embedded in 20 an observational study design. For instance, smoking status and mental disorders (e.g., depression) were 21 suggested to be risk factors for developing severe COVID-19 (Centers for Disease Control and Prevention, 22 2021b, 2021a), and this can be prevalent in people in their 30s and 40s. In addition, patients receiving AP may 23 have a higher risk of developing pneumonia than those who do not (i.e., confounding by indication). Therefore, 24 the observed association might result from residual confounders instead, and the causality cannot be inferred. 25 However, baseline characteristics between groups were mostly similar in terms of statistical (i.e., p-values) and 26 nonstatistical (i.e., eyeballing) consideration. Furthermore, since our study populations were relatively young, 27 many medical conditions that can increase the risk of severe COVID-19, such as cancer, chronic lung disease, 28 and chronic kidney disease, were rare and should not be major concerns. Additionally, the results were less 29 likely to be confounded by favipiravir as proportions of patients receiving favipiravir during admission were 30 similar between groups (i.e., 9.7% in a standard of care group versus 10.6% in an AP group).

31 Second, our results suffered from being underpowered. With the sample size of 605, we had only 11% of power 32 to detect the difference in the incidence of pneumonia between exposed (10.5%) and unexposed groups (8.7%). 33 A total of 9,000 participants would be required to achieve at least 80% of power to detect such a slight 34 difference. However, when one carefully examines the effect size and the lower and upper limit of the confidence interval (e.g., OR 1.42 [95% CI 0.79, 2.55]), increasing the sample size is prone to strengthen the 35 36 harmful signal of the association.

37 Third, our primary outcome was evaluated based solely on chest radiography by each physician leading to 38 potential misclassification bias. Nevertheless, it is likely to be a non-differential misclassification, since the same 39 data source was used to evaluate the outcome throughout, and this would bias our results toward the null. 40 Accordingly, the actual association should be more potent than our observation. Nevertheless, the results from 41 the secondary outcome were consistent with the primary one, suggesting the robustness of our findings.

Lastly, the data on viral strains was lacking, which might affect the external validity of our study. The most prevalent variants initially found in Thailand were B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma), whereas the first report of B.1.617.2 (Delta) in Thailand was back in May 2021. Hence, all four strains can be found in study patients at data collection. Nonetheless, since the incidence of pneumonia in the standard of care group in our study was similar to a previous trial (Wanaratna et al., 2021) and no death occurred, it can be assumed that the viral strains in our study were comparable to the previous trial. Additionally, our findings may limit the generalisability to unvaccinated patients. However, since the COVID-19 vaccine's efficacy in the reduction of the severity of symptoms and pneumonia has been proved and widely accepted (Jara et al., 2021), the role of

9 AP in COVID-19 may, unfortunately, become less prominent over time.

10 Implications

1

2

3

4

5

6

7

8

11 For the clinical implications, while waiting for the results from ongoing trials together with improved availability 12 of favipiravir and the COVID-19 vaccine, we suggested that physicians should suspend the use of AP to treat 13 COVID-19. This is because we observed potentially harmful effects without the proof of efficacy, even though 14 causality cannot be established. For the research implications, collaborated multicentre is required to achieve 15 a sufficient sample size and confirm our findings. In addition, the safety parameters of using AP were rarely 16 monitored. We noticed that less than one-fourth of patients receiving AP underwent liver function (e.g., AST, 17 ALT, ALP) and renal function test (e.g., Scr and eGFR) at baseline and rarely measured afterwards. Although 18 a previous study has shown the safety of AP used in other indications (Worakunphanich et al., 2021), the safety of using such a high dose of AP in COVID-19 is still unclear and needs further investigation. 19

20 Conclusion

- 21 In summary, there is insufficient evidence to show the effectiveness of AP crude extract for the treatment of
- 22 mild COVID-19 in our study. Moreover, we observed the signal that AP might potentially harm. Results from
- 23 ongoing randomised controlled trials should provide insight into this issue. In the meantime, using AP in this
- 24 condition should be cautious or suspended.

25 Acknowledgements

26 This study was financially supported by the Thailand Science Research and Innovation Fund and the University 27 of Phayao (Grant No. UoE62010). However, the funding body did not involve a study design, data collection, 28 data analysis, and study's interpretation. Additionally, we thank members of staff at Phrae hospital for facilitating

29 the data collection process of this study.

30 Authors' contribution

JT, SK, and NN conceptualised the study objectives and designed and collected the data. JT, SK, and NN 31 32 contributed to the literature reviewing, data cleaning, data analyses, and interpretation of the findings. JT 33 prepared an initial manuscript, and NN further developed subsequent manuscripts. SK, PT, NP, LS, BB, and 34 CS critically revised the initial manuscript, and all authors participated in further revisions. The final manuscript 35 was read and approved by all authors before submission.

36 **Disclaimers**

- 37 The funding body and authors' affiliations bear no responsibility for analysing and interpreting this study.
- 38

1 References

2 Centers for Disease Control and Prevention, 2021a. Underlying medical conditions associated with higher risk 3 for severe COVID-19: information for healthcare providers IWWW Document]. URL 4 https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (accessed 5 12.18.21). 6 Centers for Disease Control and Prevention, 2021b. Science brief: evidence used to update the list of 7 underlying medical conditions that increase a person's risk of severe illness from COVID-19 [WWW 8 Document]. URL https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-9 evidence-table.html?CDC AA refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-10 ncov%2Fhcp%2Fclinical-care%2Funderlying-evidence-table.html (accessed 12.18.21). Dai, Y., Chen, S.-R., Chai, L., Zhao, J., Wang, Yitao, Wang, Ying, 2019. Overview of pharmacological 11 12 activities of Andrographis paniculata and its major compound andrographolide. Crit Rev Food Sci Nutr 13 59, S17-S29. https://doi.org/10.1080/10408398.2018.1501657 14 Enmozhi, S.K., Raja, K., Sebastine, I., Joseph, J., 2021. Andrographolide as a potential inhibitor of SARS-15 CoV-2 main protease: an in silico approach. J Biomol Struct Dyn 39, 3092-3098. 16 https://doi.org/10.1080/07391102.2020.1760136 17 Jara, A., Undurraga, E.A., González, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, 18 K., Leon, F., Sans, C., Leighton, P., Suárez, P., García-Escorza, H., Araos, R., 2021. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med 385, 875-884. 19 https://doi.org/10.1056/NEJMoa2107715 20 Karbwang, J., Na-Bangchang, K., 2021. Repurposed drugs for COVID-19 treatment. J Thai Trad Alt Med 19, 21 22 285-302. 23 Phumiamorn, S., Sapsutthipas, S., Pruksakorn, P., Trisiriwanich, S., 2020. In vitro study on antiviral activity of Andrographis paniculata against COVID-19 [WWW Document]. URL https://www3.dmsc.moph.go.th/en/ 24 25 (accessed 12.21.21). 26 Rajagopal, K., Varakumar, P., Baliwada, A., Byran, G., 2020. Activity of phytochemical constituents of 27 Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach. Futur J Pharm Sci 6, 104. https://doi.org/10.1186/s43094-020-00126-x 28 29 Rattanaraksa, D., Khempetch, R., Poolwiwatchaikool, U., Nimitvilai, S., Loatrakul, O., Srimanee, P., 2021. 30 The efficacy and safety of Andrographis paniculata extract for treatment of COVID-19 patients with mild symptoms, Nakhonpathom hospital. Reg 4-5 Med J 40, 269-281. 31 32 Sa-ngiamsuntorn, K., Suksatu, A., Pewkliang, Y., Thongsri, P., Kanjanasirirat, P., Manopwisedjaroen, S., 33 Charoensutthivarakul, S., Wongtrakoongate, P., Pitiporn, S., Chaopreecha, J., Kongsomros, S., 34 Jearawuttanakul, K., Wannalo, W., Khemawoot, P., Chutipongtanate, S., Borwornpinyo, S., 35 Thitithanyanont, A., Hongeng, S., 2021. Anti-SARS-CoV-2 activity of Andrographis paniculata extract 36 and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in 37 major organ cell representatives. J Nat Prod 84, 1261-1270. 38 https://doi.org/10.1021/acs.jnatprod.0c01324 39 Thai Clinical Trials Registry, 2009. Identifier TCTR20210809004 - Comparison efficacy and safety of

1	Andrographis paniculata extract capsules and placebo in COVID-19 patients: double blind randomized
2	control trial [WWW Document]. Med Res Found. URL
3	https://www.thaiclinicaltrials.org/show/TCTR20210809004 (accessed 12.16.21).
4	Vandenbroucke, J.P., von Elm, E., Altman, D.G., Gøtzsche, P.C., Mulrow, C.D., Pocock, S.J., Poole, C.,
5	Schlesselman, J.J., Egger, M., Blettner, M., Boffetta, P., Brenner, H., Chêne, G., Cooper, C., Davey-
6	Smith, G., Gagnon, F., Greenland, P., Greenland, S., Infante-Rivard, C., Ioannidis, J., James, A.,
7	Jones, G., Ledergerber, B., Little, J., May, M., Moher, D., Momen, H., Morabia, A., Morgenstern, H.,
8	Paccaud, F., Röösli, M., Rothenbacher, D., Rothman, K., Sabin, C., Sauerbrei, W., Say, L., Sterne, J.,
9	Syddall, H., White, I., Wieland, S., Williams, H., Zou, G.Y., 2007. Strengthening the Reporting of
10	Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 4, e297.
11	https://doi.org/10.1016/j.ijsu.2014.07.014
12	Wanaratna, K., Leethong, P., Inchai, N., Chueawiang, W., Sriraksa, P., Tabmee, A., Sirinavin, S., 2021.
13	Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: a randomized
14	controlled trial (version 3). medRxiv. https://doi.org/10.1101/2021.07.08.21259912
15	Worakunphanich, W., Thavorncharoensap, M., Youngkong, S., Thadanipon, K., Thakkinstian, A., 2021.
16	Safety of Andrographis paniculata: a systematic review and meta-analysis. Pharmacoepidemiol Drug
17	Saf 30, 727–739. https://doi.org/10.1002/pds.5190
18	Zhang, X., Lv, L., Zhou, Y., Xie, L., Xu, Q., Zou, X., Ding, Y., Tian, J., Fan, J., Fan, H., Yang, Y., Ye, X.,
19	2021. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter,
20	prospective, open-label and randomized controlled trial. Phytother Res 35, 4401–4410.
21	https://doi.org/10.1002/ptr.7141
22	

1 Table 1 Baseline characteristics of study populations

Baseline characteristics	AP group	Standard of care	Total	p-value
Dasenne characteristics	(n=351)	group (n=254)	(n=605)	p-value
Male	172 (49.0)	133 (52.4)	305 (50.4)	0.42 ^a
Age (years)	34.84 ± 11.56	36.19 ± 12.13	35.41 ± 11.81	0.17 ^b
Body mass index (kg/m²) [†]	24.75 ± 5.08	23.62 ± 5.27	24.2 ± 5.17	0.32 ^b
Comorbidity				
Hypertension	24 (6.9)	20 (7.9)	44 (7.3)	0.63 ^a
Diabetes	8 (2.3)	5 (2.0)	13 (2.2)	0.80 ^a
Cardiovascular disease	4 (1.1)	1 (0.4)	5 (0.8)	0.41 ^c
Current medications				
ACEIs/ARBs	14 (4.0)	9 (3.5)	23 (3.8)	0.78 ^a
Statins	9 (2.6)	7 (2.8)	16 (2.6)	0.88 ^a
Antiplatelets	2 (0.6)	3 (1.2)	5 (0.8)	0.65 ^c
Laboratory parameters [†]				
WBC (10 ³ /mm ³)	6.33 ± 2.16	6.43 ± 1.96	6.38 ± 2.05	0.75 ^b
Lymphocyte (%)	33.01 ± 10.22	30.25 ± 10.42	31.57 ± 10.39	0.09 ^b
Neutrophil (%)	56.64 ± 11.45	58.82 ± 11.10	57.77 ± 11.29	0.21 ^b
Platelet (10 ³ /mm ³)	228.78 ± 69.02	221.62 ± 70.46	225.07 ± 69.65	0.51 ^b
BUN (mg/dL)	10.79 ± 3.20	11.58 ± 3.84	11.21 ± 3.56	0.15 ^b
Scr (mg/dL)	0.84 ± 0.22	0.82 ± 0.18	0.83 ± 0.20	0.50 ^b
eGFR (mL/min/1.73 m ²)	101.38 ± 18.85	102.12 ± 17.29	101.77 ± 17.99	0.79 ^b
LDH (units/L), median (IQR)	197 (156, 231)	192 (164, 226)	192.5 (158, 230)	0.69 ^d
AST (units/L), median (IQR)	26 (20, 37.5)	25 (19, 35)	26 (20, 36)	0.44 ^d
ALT (units/L), median (IQR)	34 (22.5, 50.5)	35 (23,52)	34 (23, 51)	0.92 ^d
ALP (units/L), median (IQR)	77.5 (63, 88)	66 (58, 77)	70 (60, 83)	0.004 ^d


2 Notes: Figures represent mean ± SD and frequency (%) unless specified elsewhere, "Chi-squared test, "Student's t-test with 3 equal variance, ^cFisher's exact test, ^dWilcoxon rank-sum test, [†]Missing values of each covariate were as follows: 83.6% (BMI), 4 72.4% (WBCs), 72.4% (Lymphocyte), 72.4% (Neutrophil), 72.6% (Platelet), 71.9% (BUN), 71.9% (Scr), 72.1% (eGFR), 79.2% 5 (LDH), 72.7% (AST), 72.7% (ALT), and 72.7% (ALP), Abbreviations: AP; Andrographis paniculata, SD; standard deviation, 6 ACEIs/ARBs; angiotensin-converting enzyme inhibitors/ angiotensin-receptor blockers, BUN; blood urea nitrogen, Scr; serum 7 creatinine, eGFR; estimated glomerular filtration rate, LDH; lactate dehydrogenase, AST; aspartate transaminase, ALT; alanine 8 transaminase, ALP; alkaline phosphatase, WBC; white blood cell

9


1 Table 2 Efficacy of AP's use in mild COVID-19 patients

	Events (%)		Effect size (95% Cl)*, p-value (n=605)		
Outcomes	AP	Standard of	Unadjusted	Age-adjusted	Fully adjusted
	(n=351)	care (n=254)	model	model	model [†]
Primary outcome	: pneumonia				
Odds ratio	37 (10.5)	22 (8.7)	1.24	1.42	1.42
			(0.71, 2.16),	(0.80, 2.54),	(0.79, 2.55),
			0.44	0.23	0.24
Hazard ratio [‡]	13.93 [§]	12.47 [§]	1.11	1.26	1.26
	(10.09, 19.23)	(8.21, 18.94)	(0.66, 1.89) [‡] ,	(0.74, 2.15) [‡] ,	(0.74, 2.17) [‡] ,
			0.69	0.39	0.40
Secondary outco	me: worsening sy	mptoms [¶]			
Odds ratio	59 (16.8)	39 (15.4)	1.11	1.23	1.22
			(0.72, 1.73),	(0.78, 1.94),	(0.77, 1.94),
			0.63	0.38	0.39

2 Notes: *Effect size of outcome in the AP group, compared to the standard of care group, [†]Adjusting for age, diabetes, hypertension, receiving statins, and receiving ACEIs/ARBs, [§]Incidence rate of pneumonia per 1,000 3 person-days (95% confidence interval), [‡]Analysis using a Cox's proportional hazards model in which the fully 4 adjusted model was additionally stratified by diabetes, [¶]Worsening symptoms were the composite of receiving 5 6 antiviral drugs, systemic corticosteroids, or ventilator support; having oxygen saturation drop along with 7 worsening signs and symptoms; or presenting regressive chest X-rays findings (i.e., category three or above). 8 Abbreviations: AP; Andrographis paniculata, CI; confidence interval 9



19



1

2 Figure 2 Subgroup analysis of Andrographis paniculata and the occurrence of pneumonia

3 Notes: Odds ratios were adjusted for age, hypertension, diabetes mellitus, previous ACEIs/ARBs therapy, and

4 previous statins therapy. Abbreviations: ACEIs/ARBs; angiotensin-converting enzyme inhibitors/ angiotensin

5 receptor blockers, aOR; adjusted odds ratio, AP; Andrographis paniculata, CI; confidence interval, Std of care;

6 standard of care

Supplementary Appendices

This is supplement to 'the efficacy of Andrographis paniculata (Burm.f.) Wall. ex Nees crude extract in hospitalised mild COVID-19 patients: a retrospective cohort study'

Quality assurance of Andrographis paniculata product (exposure) used in Phrae hospital4
Modified Rama Co-RADS for first chest X-rays in confirmed COVID-19 patients
Systematic search
eReferences16
Table S1 STROBE checklist for cohort study
Table S2 Summary of five ongoing trials of Andrographis paniculata used in COVID-19 patients in Thailand8
Table S3 Incidence rate of pneumonia by follow-up time 9
Table S4 Incidence rate of pneumonia according to age groups 10
Table S5 The association between baseline characteristics and incident pneumonia 11
Table S6 Sensitivity analyses of andrographolide and efficacy outcomes
Figure S1 Directed acyclic graphs (DAGs) of the association between Andrographis paniculata and incidence
of pneumonia13
Figure S2 Probability of pneumonia-free event by exposure14
Figure S3 The distribution of hospital admission dates between Andrographis paniculata group and standard
of care group15

Table S1 STROBE checklist for cohort study

	Item	Recommendation	Page
	No.		No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the	3
		title or the abstract	
		(b) Provide in the abstract an informative and balanced summary	
		of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	4
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including	4-5
		periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	4-5
•		selection of participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of	
		exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	5
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	5
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	5-6
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control	5-6
	12	for confounding	00
		(b) Describe any methods used to examine subgroups and	
		interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(<u>e</u>) Describe any sensitivity analyses	
Results	10*	(a) Depart numbers of individuals at each stars of study.	с г:
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	6, Fię
		numbers potentially eligible, examined for eligibility, confirmed	1
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	

	ltem	Recommendation	Page
	No.		No.
Outcome data	15*	Report numbers of outcome events or summary measures over	6-7,
		time	Table
			S3-4,
			FigS2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-	6-7,
		adjusted estimates and their precision (eg, 95% confidence	Table
		interval). Make clear which confounders were adjusted for and	2
		why they were included	
		(b) Report category boundaries when continuous variables were	
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	Fig 2
		interactions, and sensitivity analyses	Table
<u> </u>			S6
Discussion	10		7
Key results	18	Summarise key results with reference to study objectives	7
Limitations	19	Discuss limitations of the study, taking into account sources of	8-9
		potential bias or imprecision. Discuss both direction and	
		magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	7-9
		objectives, limitations, multiplicity of analyses, results from similar	
		studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
Other information			
Funding	22	Give the source of funding and the role of the funders for the	10
		present study and, if applicable, for the original study on which the	
		present article is based	

*Give such information separately for cases and controls in case-control studies, and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Quality assurance of Andrographis paniculata product (exposure) used in Phrae hospital

Certificate of analysis: The analysis and quality control reported from the Medicinal Plant Research Institute and the regional Medical Sciences Center 1/1, Chiang Rai, Thailand

Test	Results	Methods	Acceptance criteria
Total lactones content,	6.0 %w/w	Thai Herbal	Not less than 6.0 %w/w
calculated as andrographolide		Pharmacopoeia	
Andrographolide content	4.16 %w/w	Thai Herbal	Not less than 1.0 %w/w
		Pharmacopoeia	of andrographolide
Basic chemical tests	Complied with the	Thai Herbal	Positive
(Phytochemical tests)	standard	Pharmacopoeia 2017	
Chemical Identification by	Complied with the	Thai Herbal	Complied with the
Thin-Layer Chromatography	standard	Pharmacopoeia 2017	standard of
			Andrographis
			<i>paniculata</i> (Burm. f.)
			Wall. ex Nees
Moisture content analysis by	5.5 %w/w	Thai Herbal	Not more than 11.0
gravimetric analysis		Pharmacopoeia 2017	%w/w
Acid-insoluble ash	0.2 %w/w	Thai Herbal	Not more than 2.0
		Pharmacopoeia 2017	%w/w
Ethanol (85%)-soluble	17.9 %w/w	Thai Herbal	Not less than 13.0
extractive		Pharmacopoeia 2017	%w/w
Water-soluble extractive	20.9 %w/w	Thai Herbal	Not less than 18.0
		Pharmacopoeia 2017	%w/w
Weight variation	Complied with the	Thai Herbal	Not more than 2
	standard	Pharmacopoeia 2017	capsules with weight
			variation beyond the
			range of +/- 10% and
			no individual capsule
			with weight variation
			beyond the range of +/-
			20%
Disintegration time	8 minutes	Thai Pharmacopoeia	All shall be
		1997 Volume II Part 1	disintegrated within 30
			minutes.
Total aerobic microbial count	Less than 10	Thai Herbal	Not more than 500,000
per gram or milliliter		Pharmacopoeia	cfu per gram or milliliter
Total combined yeast and	Less than 10	Thai Herbal	Not more than 50,000
mold count per gram or		Pharmacopoeia	cfu per gram or milliliter
milliliter			
Bile-tolerant gram-negative	Less than 10	Thai Herbal	Not more than 1,000
bacteria per gram or milliliter		Pharmacopoeia	cfu per gram or milliliter

Test	Results	Methods	Acceptance criteria
Salmonella spp. per 10 Not found		Thai Herbal	Not found per 10
grams or milliliter		Pharmacopoeia	grams or milliliter
Escherichia coli per gram or	Not found	Thai Herbal	Not found per grams or
milliliter		Pharmacopoeia	milliliter
Clostridium spp. per gram or	Not found	Thai Herbal	Not found per grams or
milliliter		Pharmacopoeia	milliliter
Identification A, B, C	A=Purplish color	Thai Herbal	Complied with the
	B=Yellow color	Pharmacopoeia	standard
	C=Find dark violet		
	spot chromatogram		
Loss on drying	5.61% w/w	Thai Herbal	Not more than 11.0
		Pharmacopoeia	%w/w
Ethanol-soluble extractive	18.49 %w/w	Thai Herbal	Not less than 13.0
		Pharmacopoeia	%w/w
Water-soluble extractive	21.31 %w/w	Thai Herbal	Not less than 18.0
		Pharmacopoeia	%w/w
Acid-insoluble ash	0.004 %w/w	Thai Herbal	Not more than 2.0
		Pharmacopoeia	%w/w

Abbreviations: cfu; colony-forming unit, %w/w; percentage weight by weight

Modified Rama Co-RADS for first chest X-rays in confirmed COVID-19 patients

Source (Suwatanapongched et al., n.d.)

Categories 1-6 and C are for the initial chest X-rays (CXR) in a new patient or the first CXR in a home isolation or community isolation patient. In this regard, whenever the patient has an old CXR before having COVID-19, the newly performed CXR after confirmed COVID-19 should be interpreted using categories 1, 2, 3, 4, 5, 6, or C. Details of each category were as follows:

- Category 1: Normal chest X-ray or no abnormality detected
- Category 2: Presence of minor abnormalities unrelated to COVID-19 (e.g., mild cardiomegaly, aortic atherosclerosis, scoliosis, old fractures)
- Category C: Low likelihood or atypical for COVID-19 pneumonia, but with other clinically significant diseases (e.g., bacterial pneumonia, active TB, CHF, pneumothorax, pleural effusion, malignancy) unrelated to COVID-19
- Category 3: Equivocal/indeterminate opacities, which may be due to acute or residual/post-COVID-19 pneumonia or pseudolesions
- Category 4: Single or multifocal poorly defined ground-glass opacities or consolidations in one lung, suspicious for early/mild acute or post-COVID-19 pneumonia ± fibrosis-like changes
- Category 5: Multifocal, peripheral, poorly defined ground-glass opacities or consolidations with or without rounded morphology involving any zones of both lungs, typical for moderate/severe acute or post-COVID-19 pneumonia ± fibrosis-like changes
- Category 6: Acute or post-COVID-19 pneumonia with its related conditions or complications (e.g., PE, pulmonary infarction, OP, AFOP, secondary infection, atelectasis, pneumothorax, pneumomediastinum)

Systematic search

PubMed

("COVID-19"[All Fields] OR "COVID-19"[MeSH Terms] OR "COVID-19 Vaccines"[All Fields] OR "COVID-19 Vaccines"[MeSH Terms] OR "COVID-19 serotherapy"[All Fields] OR "COVID-19 serotherapy"[Supplementary Concept] OR "covid 19 nucleic acid testing"[All Fields] OR "covid 19 nucleic acid testing"[MeSH Terms] OR "covid 19 serological testing"[All Fields] OR "covid 19 nucleic acid testing"[MeSH Terms] OR "covid 19 serological testing"[All Fields] OR "covid 19 nucleic acid testing"[MeSH Terms] OR "covid 19 testing"[All Fields] OR "covid 19 serological testing"[MeSH Terms] OR "covid 19 testing"[MeSH Terms] OR "sars cov 2"[All Fields] OR "sars cov 2"[MeSH Terms] OR "Severe Acute Respiratory Syndrome Coronavirus 2"[All Fields] OR "NCOV"[All Fields] OR "2019 NCOV"[All Fields] OR (("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields] OR "COV"[All Fields]) AND 2019/11/01:3000/12/31[Date - Publication])) AND ("andrographolide"[Supplementary Concept] OR "Andrographis paniculata"[Text Word] OR "Andrographis paniculata extract"[Text Word] OR "andrographolide"[Text Word])

Searching on 15/12/2021 without language restriction yielded 43 results: found no relevant clinical studies.

Google Scholar

("andrographis" OR "Andrographis paniculata" OR "andrographolide") AND ("sars-cov2" OR "sars cov 2" OR "covid-19" OR "covid") restricted to the range between 2019 and 2021 Searching on 15/12/2021 without language restriction yielded 1,460 results: found 2 relevant

studies(Rattanaraksa et al., 2021; Wanaratna et al., 2021).

Thai Clinical Trial Registry (TCTR)

There are seven currently registered RCTs. Two are completed RCTs: One small pilot study with no published results (n=6), another one can be found at <u>https://doi.org/10.1101/2021.07.08.21259912</u> (n=57) (Wanaratna et al., 2021). Additionally, there are five ongoing RCTs (Table S2), including the largest one (n=736) anticipated to complete in October 2022 (Thai Clinical Trials Registry, 2009a).

 Table S2
 Summary of five ongoing trials of Andrographis paniculata used in COVID-19 patients in Thailand

Trial	TCTR 20210514003(Thai	TCTR 20210609001(Thai	TCTR 20210809004(Thai	TCTR 20210906002(Thai	TCTR 20211022002(Thai
	Clinical Trials Registry,	Clinical Trials Registry,	Clinical Trials Registry,	Clinical Trials Registry,	Clinical Trials Registry,
	2009b)	2009c)	2009d)	2009e)	2009a)
Main sponsor	DTAM	Chulabhorn Royal	Thammasat university	Chulalongkorn University	Health Systems Research
		Academy			Institute
Patient	Asymptomatic COVID-19	Mild to moderate COVID-	Asymptomatic or mild	Mild to moderate COVID-	Asymptomatic or mild
	patients (n=160)	19 patients (n=146)	COVID-19 patients (n=186)	19 patients (n=160)	COVID-19 patients without
					pneumonia (n=736)
Intervention	Andrographolide 180	Andrographolide 180	Andrographolide 180	Andrographolide 180 mg	Andrographis capsule 180
	mg/day for 5 days	mg/day for 5 days +	mg/day	for 5 days + Favipiravir	mg/day for 5 days
		Favipiravir 3.6 g day 1 then		(200 mg) 9x2 for 1 day	
		1.6 g/ day for 4 days		then 4x2 for 4 days.	
Comparator	Placebo	Favipiravir 3.6 g day 1 then	Placebo	Favipiravir (200 mg) 9x2 for	Placebo
		1.6 g/ day * 4 days		1 day then 4x2 for 4 days	
				alone.	
Primary	Hospitalisation rate during	Clinical stable or	Symptoms and severity	Proportion of patients	Pneumonia at day 10
outcome	14 days of follow-up	improvement of symptom	score until discharge	developing severe	
		at day 4		pneumonia at 6 months	
Study design	Randomised, double blind,	Randomised, double blind,	Randomised, double blind,	Randomised, open label,	Randomised, double blind,
	placebo-controlled trial	placebo-controlled trial	placebo-controlled trial	active-controlled trial	placebo-controlled trial
Status	Pending (ethic submitted)	Not yet recruiting	Recruiting	Pending (ethic submitted)	Not yet recruiting
Updated in TCTR	14 May 2021	9 Jun 2021	26 Aug 2021	6 Sep 2021	22 Oct 2021

Notes: Updated on 15 Dec 2021, Abbreviations: DTAM; Department of Thai Traditional and Alternative Medicine, TCTR; Thai Clinical Trial Registry

Group	Events	Person-days of follow-up	Incidence rate per 1,000 person-days (95% CI)
Andrographis pani	<i>iculata</i> group		
Before 7 days	31	2,203	14.07 (9.90, 20.01)
After 7 days	6	453	13.25 (5.95, 29.48)
Overall	37	2,656	13.93 (10.09, 19.23)
Standard of care g	roup	·	
Before 7 days	20	1,470	13.61 (8.78, 21.09)
After 7 days	2	294	6.80 (1.70, 27.20)
Overall	22	1,764	12.47 (8.21, 18.94)
Total		·	
Before 7 days	51	3,673	13.89 (10.55, 18.27)
After 7 days	8	747	10.71 (5.36, 21.41)
Overall	59	4,420	13.35 (10.34, 17.23)

Group	Events	Person-days of follow-up	Incidence rate per 1,000 person-days (95% CI)
Andrographis pan	<i>iculata</i> group		
Age <60	31	2,557	12.12 (8.53, 17.24)
Age 60+	6	99	60.61 (27.23, 134.90)
Overall	37	2,656	13.93 (10.09, 19.23)
Standard of care g	Iroup		
Age <60	20	1,683	11.88 (7.67, 18.42)
Age 60+	2	81	24.69 (6.18, 98.73)
Overall	22	1,764	12.47 (8.21, 18.94)
Total		·	
Age <60	51	4,240	12.03 (9.14, 15.83)
Age 60+	8	180	44.44 (22.23, 88.87)
Overall	59	4,420	13.35 (10.34, 17.23)

Table S4 Incidence rate of pneumonia according to age groups

Deseline shewesteristics	Pneumonia		Total				
Baseline characteristics	Yes (n=59)	No (n=546)	(n=605)	p-value			
Male	31 (52.5)	274 (50.2)	305 (50.4)	0.73			
Age (years)	44.71 (12.57)	34.40 (11.29)	35.41 (11.81)	<0.001			
Body mass index (kg/m²) [†]	26.04 (4.07)	23.96 (5.28)	24.2 (5.17)	0.23			
Comorbidity							
Hypertension	11 (18.6)	33 (6.0)	44 (7.3)	<0.001			
Diabetes	5 (8.47)	8 (1.5)	13 (2.2)	<0.001			
Cardiovascular disease	0	5 (0.9)	5 (0.8)	1.00			
Current medications							
ACEIs/ARBs	7 (11.9)	16 (2.9)	23 (3.8)	0.001			
Statins	6 (10.2)	10 (1.8)	16 (2.6)	<0.001			
Antiplatelets	0	5 (0.9)	5 (0.8)	1.00			
Laboratory parameters [†]							
WBC (10 ³ /mm ³)	6.31 (1.70)	6.40 (2.16)	6.38 (2.05)	0.80			
Lymphocyte (%)	26.79 (9.36)	33.03 (10.28)	31.57 (10.39)	0.001			
Neutrophil (%)	62.69 (11.11)	56.27 (10.95)	57.77 (11.29)	0.002			
Platelet (10 ³ /mm ³)							
Mean (SD)	218.74 (70.12)	227.01 (69.67)	225.07 (69.65)	0.52			
Median (IQR)	209 (155, 255)	218 (181, 261)	215.5 (178, 260)				
BUN (mg/dL)	11.23 (3.85)	11.20 (3.49)	11.21 (3.56)	0.96			
Scr (mg/dL)	0.84 (0.17)	0.83 (0.21)	0.83 (0.20)	0.89			
eGFR (mL/min/1.73m ²)	97.52 (15.16)	103.05 (18.62)	101.77 (18.0)	0.09			
LDH (units/L), median (IQR)	188.5 (155, 228)	201.5 (172.5, 230.5)	192.5 (158, 230)	0.14			
AST (units/L), median (IQR)	26 (22, 38)	26 (20, 36)	26 (20, 36)	0.25			
ALT (units/L), median (IQR)	35 (25, 47)	34 (22, 55)	34 (23, 51)	0.81			
ALP (units/L), median (IQR)	70 (58, 88)	70.5 (61, 83)	70 (60, 83)	0.96			

Table S5 The association between baseline characteristics and incident pneumonia

	Odds ratio (95% confidence interval)*, p-value						
Outcomes	Unadjusted	Age-adjusted	Fully adjusted	Additional adjusting			
	model	model	$model^\dagger$	model ^{††}			
Total participants (n=605, events=59)							
Primary outcome							
Pneumonia	1.24 (0.71, 2.16),	1.42 (0.80, 2.54),	1.42 (0.79, 2.55),	1.29 (0.68, 2.46),			
	0.44	0.23	0.24	0.44			
Pneumonia [‡]	1.12 (0.66, 1.89) [‡] ,	1.27 (0.75, 2.16) [‡] ,	1.27 (0.74, 2.17) [‡] ,	1.20 (0.67, 2.13) [‡] ,			
	0.68	0.38	0.39	0.54			
Secondary outcome							
Worsening	1.11 (0.72, 1.73),	1.23 (0.78, 1.94),	1.22 (0.77, 1.94),	1.21 (0.74, 1.98),			
symptoms¶	0.63	0.38	0.39	0.45			
Excluding participants admitted before the 1 st of July, 2021 (n=545, events=49)							
Primary outcome							
Pneumonia	1.83 (0.93, 3.61),	1.94 (0.97, 3.92),	1.88 (0.92, 3.81),	1.72 (0.78, 3.79),			
	0.08	0.06	0.08	0.18			
Pneumonia [‡]	1.57 (0.82, 3.02) [‡] ,	1.57 (0.82, 3.03) [‡] ,	1.55 (0.80, 3.02) [‡] ,	1.48 (0.72, 3.03) [‡] ,			
	0.18	0.17	0.19	0.29			
Secondary outcome							
Worsening	1.34 (0.82, 2.21),	1.39 (0.83, 2.33),	1.38 (0.82, 2.33),	1.32 (0.74, 2.36),			
symptoms¶	0.25	0.21	0.22	0.19			

Table S6 Sensitivity analyses of Andrographis paniculata and efficacy outcomes

Г

Τ

Notes: *Analysis using multiple imputation by chain equation (MICE), [†]Adjusting for age, diabetes, hypertension, receiving statins, and ACEIs/ARBs, [§]Incidence rate of pneumonia per 1,000 person-days (95% confidence interval), [‡]Cox's proportional hazards model, in which fully adjusted model was additionally stratified by diabetes, and effect sizes were reported as hazard ratio (95% CI). ^{††}Additional adjusting model was a fully adjusting model with further adjusting for body mass index. [¶]Worsening symptoms were the composite of receiving antiviral drugs, systemic corticosteroids, or ventilator support; having oxygen saturation drop along with worsening signs and symptoms; or presenting regressive chest X-rays findings (i.e., category three or above).




Figure S1 Directed acyclic graphs (DAGs) of the association between Andrographis paniculata and incidence of pneumonia

Abbreviations: ACEIs/ARBs; angiotensin converting enzyme inhibitors/ angiotensin receptor blockers, BMI; body mass index, T2DM; type 2 diabetes mellitus, Sources:(Centers for Disease Control and Prevention, 2021a, 2021b)




Figure S2 Probability of a pneumonia-free event by exposure

Abbreviation: AP; Andrographis paniculata




Figure S3 The distribution of hospital admission dates between Andrographis paniculata group and standard of care group

Notes: A vertical dotted line represents the 1st of July, 2021. Abbreviations: AP; Andrographis paniculata

eReferences

Centers for Disease Control and Prevention, 2021a. Science brief: evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19 [WWW Document]. URL https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fclinical-care%2Funderlying-evidence-table.html (accessed 12.18.21).

Centers for Disease Control and Prevention, 2021b. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [WWW Document]. URL https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (accessed 12.18.21).

- Rattanaraksa, D., Khempetch, R., Poolwiwatchaikool, U., Nimitvilai, S., Loatrakul, O., Srimanee, P., 2021.
 The efficacy and safety of Andrographis paniculata extract for treatment of COVID-19 patients with mild symptoms, Nakhonpathom hospital. Reg 4-5 Med J 40, 269–281.
- Suwatanapongched, T., Nitiwarangkul, C., Taweesakulvashra, R., Chitrapazt, N., n.d. Modified Rama Co-RADS user guideline [WWW Document]. URL

https://med.mahidol.ac.th/radiology/th/knowledge/radiology/09012021-1113-th (accessed 12.11.21).

- Thai Clinical Trials Registry, 2009a. Identifier TCTR20211022002 Efficacy and safety of an Andrographis capsule compared with standard therapy for the treatment of asymptomatic or mild COVID-19 without pneumonia : a double-blinded randomized-control trial [WWW Document]. Med Res Found. URL https://www.thaiclinicaltrials.org/show/TCTR20211022002 (accessed 12.16.21).
- Thai Clinical Trials Registry, 2009b. Identifier TCTR20210514003 Andrographolide as a medical tool for reduction of hospitalization in mild or asymptomatic COVID-19 patients: a randomized double-blind placebo controlled trial [WWW Document]. Med Res Found. URL https://www.thaiclinicaltrials.org/show/TCTR20210514003 (accessed 12.16.21).
- Thai Clinical Trials Registry, 2009c. Identifier TCTR20210609001 Efficacy of Andrographis paniculata extract combined with favipiravir treatment to prevent disease progression in mild to moderate COVID-19 patients: a double-blind, randomized, placebo-controlled study [WWW Document]. Med Res Found. URL https://www.thaiclinicaltrials.org/show/TCTR20210609001 (accessed 12.16.21).
- Thai Clinical Trials Registry, 2009d. Identifier TCTR20210809004 Comparison efficacy and safety of Andrographis paniculata extract capsules and placebo in COVID-19 patients: double blind randomized control trial [WWW Document]. Med Res Found. URL

https://www.thaiclinicaltrials.org/show/TCTR20210809004 (accessed 12.16.21).

Thai Clinical Trials Registry, 2009e. Identifier TCTR20210906002 - Prospective study of Andrographolide and favipiravir versus favipiravir monotherapy to prevent severe pulmonary involvement in patients with COVID-19 [WWW Document]. Med Res Found. URL

https://www.thaiclinicaltrials.org/show/TCTR20210906002 (accessed 12.16.21).

Wanaratna, K., Leethong, P., Inchai, N., Chueawiang, W., Sriraksa, P., Tabmee, A., Sirinavin, S., 2021. Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: a randomized controlled trial (version 3). medRxiv.